BGBC016 STK11 NSCLC (Non-Small Cell Lung Cancer)

Purpose of this Study

We are doing this study to find out if an investigational drug called bemcentinib (the study drug) is a safe and effective option when it is combined with the standard therapy for non-small cell lung cancer (1 immunotherapy drug and 2 chemotherapy drugs).

Who Can Participate?

Eligibility

Adults ages 18+ who are diagnosed with advanced non-squamous non-small cell lung cancer. For more information about who can be in this study, please contact the study team at annmarie.peters@duke.edu.

What is Involved?

Description

If you join this study, you will go through a screening period to make sure you are eligible. During the screening period you will:
  • Have blood draws
  • Have imaging scans (CT and MRI)
  • Have 2 procedures to check your heart function, an electrocardiogram (ECG) and either an echocardiogram (ECHO) or a multigated acquisition scan (MUGA)
If you are eligible to get the study drug, you will:
  • Take the study drug by month once per day
  • Received the standard therapy (1 immunotherapy drug and 2 chemotherapy drugs) every 21 days by injection into a vein (IV)

    • Study Details

    Full Title

    Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation. (BGBC016 STK11 NSCLC)

    Principal Investigator

    Laura
    Alder

    Protocol Number

    PRO00112972

    NCT ID

    NCT05469178

    Phase

    I/II

    Enrollment Status

    Open to Enrollment
    ClinicalTrials.gov